N/A
N=385
Virtual Reality Therapy for Chronic Low Back Pain
Chronic Low Back Pain
Bottom Line
View on ClinicalTrials.gov: NCT04409353 ↗Enrolled (actual)
385
Serious AEs
1.8%
Results posted
Mar 2025
Primary outcome: Primary: Change From Baseline in Patient-Reported Outcomes Measurement Information System Pain Interference (PROMIS-PI) at Day 30 — -1.15; -1.86; -1.67 units on a scale — p=0.4884
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Distraction-Based VR (Device); Sham VR (Device); Skills-Based VR (Device); Activity Tracker (Device)
- Age
- Pediatric, Adult, Older Adult · 13+ yrs
- Sex
- All
- Sponsor
- Cedars-Sinai Medical Center
- Primary completion
- Oct 2023
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change From Baseline in Patient-Reported Outcomes Measurement Information System Pain Interference (PROMIS-PI) at Day 30 |
-1.15; -1.86; -1.67 | 0.4884 |
| SECONDARY Change From Baseline in Patient-Reported Outcomes Measurement Information System Pain Interference (PROMIS-PI) at Day 60 and Day 90 |
-1.32; -2.41; -2.79; -1.45; -2.79; -3.51 | 0.3101 |
| SECONDARY Change From Baseline in Pain Catastrophizing Survey Short Form 6 (PCS SF-6) at Day 90. |
-1.38; -3.04; -3.27 | .0180 sig |
| SECONDARY Change From Baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety at Day 90 |
-1.89; -2.88; -1.97 | 0.7338 |
| SECONDARY Change From Baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance to Day 90 |
-2.08; -2.44; -2.76 | 0.1833 |
| SECONDARY Change From Baseline to Day 90 in Weekly Average Opioid Usage |
41; 36; 40; 26; 26; 30 | 0.1913 |
Summary
This study will test the efficacy of an evidence-based virtual reality (VR) therapy program as a non-pharmacological supplement for the management of chronic lower back pain. Study participants will be randomized to receive one of three VR programs: Skills-Based VR, Distraction VR, or Sham VR. In addition to a VR headset, all participants will receive a Fitbit Charge 4 watch. Study devices will be delivered to the participant's home with instructions for use via FedEx; participants will receive remote technical support. They will be followed for 90 days and complete Patient Reported Outcome (PRO) questionnaires to assess functional status, pain levels, and use of pain medications (including opioids). Participants will also be asked to provide consent/authorization to access medical records from their treating facility.
Eligibility Criteria
Inclusion Criteria
- Able to provide consent to participate in research
- Stated willingness to comply with all study procedures and availability for the duration of the study
- Male or female, age 13 or older
- An ongoing low back-pain problem that has persisted at least 3 months and has resulted in pain on at least half the days in the past 6 months.
- Ability to comprehend spoken and written English
- Owns a compatible android or iOS smartphone, or personal laptop or desktop computer (excluding tablets) to complete surveys and has access to email.
Exclusion Criteria
- Presents with a condition that interferes with virtual reality usage, including history of seizure, facial injury precluding safe placement of headset, significant visual or hearing impairment that impacts ability to see the virtual reality images or follow audio instructions
- Are being recommended for long-term hospitalization that would require more than three-week stay in the hospital
- Received surgical procedure within the previous 8 weeks
- Surgery is planned within the next 3 months
- Is currently using a spinal cord stimulator
- Has low back pain attributable to a recognizable, specific pathology, including spinal infection, cancer, fracture, or inflammatory spondylopathies, consistent with the NIH Task force on Research Standards for chronic low back pain
- Previously participated in a virtual reality clinical trial
Data sourced from ClinicalTrials.gov (NCT04409353). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.